Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014
Fresenius Medical Care AG : Release of a capital market information
20.07.2026 / 12:14 CET/CEST
Dissemination of a Post-admission Duties announcement transmitted by - a service of .
The issuer is solely responsible for the content of this announcement.
Fresenius Medical Care AG: Share buyback
Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014
Share buyback – Interim Report
In the period from July 13, 2026 to July 17, 2026 (each inclusive), 336,000 shares were bought back within the framework of the first tranche of the share buyback of Fresenius Medical Care AG, the start of which was disclosed on May 28, 2026, pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No. 596/2014, Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.
Shares were bought back as follows:
| DateAcquired shares (number)Weighted average price (in EUR)Transaction volume (in EUR)Trading venue | 13 July 202631,00042.37041,313,482.40XETR | 14 July 20261,00042.534342,534.30XETR | 15 July 2026140,00041.55385,817,532.00XETR | 16 July 202684,00041.93863,522,842.40XETR | 17 July 202680,00042.20663,376,528.00XETR |
A total of 3,294,040 shares has been acquired within the framework of the first tranche of the share buyback.
The purchase of the shares is carried out by a credit institution commissioned by Fresenius Medical Care AG.
Fresenius Medical Care AG will provide regular information regarding the progress of the share buyback, including by posting its required disclosures at .
20.07.2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
| Language:English | Company:Fresenius Medical Care AG | Else-Kröner-Straße 1 | 61352 Bad Homburg | Germany | Internet:www.freseniusmedicalcare.com | LEI Code:549300CP8NY40UP89Q40 |
| End of NewsEQS News Service |
2368546 20.07.2026 CET/CEST Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.